Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

Journal Browser

Acute Coronary Syndrome (ACS): Guidelines and Evolving Concepts in the Diagnosis, Treatment and Management

Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 14753

Share This Special Issue

Special Issue Editors

Dr. Giuseppe Andò

E-Mail Website
Guest Editor

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
Interests: acute coronary syndrome; percutaneous coronary intervention (PCI); guidelines; oral anticoagulants (OAC); atrial fibrillation
Special Issues, Collections and Topics in MDPI journals

Dr. Francesco Costa

E-Mail Website
Guest Editor

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
Interests: acute coronary syndrome; percutaneous coronary intervention (PCI); guidelines; dual antiplatelet therapy (DAPT); risk scores; high bleeding risk patients

Dr. Antonio Micari

E-Mail Website
Guest Editor

Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy
Interests: acute coronary syndrome; percutaneous coronary intervention (PCI); carotid artery disease; peripheral artery disease; drug-eluting balloons; structural cardiac interventions

Special Issue Information

Dear Colleagues,

There has been considerable progress in the management of ACS over the last twenty years. The understanding of the pathophysiology of intracoronary thrombosis from plaque erosion or rupture has paved the way for the evaluation of potent antithrombotic agents in the setting of ACS. Progressive developments in techniques and technologies for percutaneous coronary intervention have dramatically improved procedural effectiveness and safety and patients’ outcomes. However, acute presentations of coronary artery disease and their late consequences remain a leading cause of morbidity and mortality. While guidelines issued by scientific societies (1) summarize and evaluate available evidence to facilitate clinicians in their decision making for daily practice and (2) provide quality indicators to evaluate the implementation of proposed recommendations, continuously evolving research introduces new diagnostic algorithms and challenges therapeutic concepts. The present Special Issue has been conceived to provide an overview of the latest evidence in the field of ACS, focusing on both diagnostic and therapeutic advances and highlighting their implications for patients’ prognosis. Therefore, we welcome the submission of review articles as well as original research papers dealing with the topics of diagnostic and therapeutic advances in patients with ACS.

Dr. Giuseppe Andò
Dr. Francesco Costa
Dr. Antonio Micari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

percutaneous coronary intervention (PCI)
high-sensitivity cardiac troponins
cardiogenic shock
ST-elevation myocardial infarction (STEMI)
non-st-elevation acute coronary syndrome (NSTE-ACS)
coronary artery disease
dual antiplatelet therapy (DAPT)
oral anticoagulants (OAC)
atrial fibrillation

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (6 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 170 KiB

Open AccessEditorial

Advances in Acute Coronary Syndromes: Bridging Gaps in Diagnosis and Treatment

by Giuseppe Andò, Antonio Micari and Francesco Costa

J. Clin. Med. 2024, 13(19), 6003; https://doi.org/10.3390/jcm13196003 - 9 Oct 2024

Viewed by 578

Abstract

Acute coronary syndromes (ACS) have long posed a formidable challenge to cardiovascular care, despite significant advancements in both understanding and treatment over the last few decades [...] Full article

(This article belongs to the Special Issue Acute Coronary Syndrome (ACS): Guidelines and Evolving Concepts in the Diagnosis, Treatment and Management)

Research

Jump to: Editorial, Review

15 pages, 869 KiB

Open AccessArticle

Contemporary Predictors of Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention: A Nationally Representative US Sample

by Benjamin D. Horne, Nipun Atreja, John Venditto, Thomas Wilson, Joseph B. Muhlestein, Joshua R. St. Clair, Kirk U. Knowlton, Naeem D. Khan, Narinder Bhalla and Jeffrey L. Anderson

J. Clin. Med. 2024, 13(10), 2844; https://doi.org/10.3390/jcm13102844 - 11 May 2024

Cited by 1 | Viewed by 1787

Abstract

Background: Patient outcomes after percutaneous coronary intervention (PCI) have improved over the last 30 years due to better techniques, therapies, and care processes. This study evaluated contemporary predictors of post-PCI major adverse cardiovascular events (MACE) and summarized risk in a parsimonious risk prediction model. Methods: The Cardiovascular Patient-Level Analytical Platform (CLiPPeR) is an observational dataset of baseline variables and longitudinal outcomes from the American College of Cardiology’s CathPCI Registry^® and national claims data. Cox regression was used to evaluate 2–6 years of patient follow-up (mean: 2.56 years), ending in December 2017, after index PCI between 2012 and 2015 (N = 1,450,787), to examine clinical and procedural predictors of MACE (first myocardial infarction, stroke, repeat PCI, coronary artery bypass grafting, and mortality). Cox analyses of post-PCI MACE were landmarked 28 days after index PCI. Results: Overall, 12.4% (n = 179,849) experienced MACE. All variables predicted MACE, with cardiogenic shock, cardiac arrest, four diseased coronary vessels, and chronic kidney disease having hazard ratios (HRs) ≥ 1.50. Other major predictors of MACE were in-hospital stroke, three-vessel disease, anemia, heart failure, and STEMI presentation. The index revascularization and discharge prescription of aspirin, P2Y₁₂ inhibitor, and lipid-lowering medication had HR ≤ 0.67. The primary Cox model had c-statistic c = 0.761 for MACE versus c = 0.701 for the parsimonious model and c = 0.752 for the parsimonious model plus treatment variables. Conclusions: In a nationally representative US sample of post-PCI patients, predictors of longitudinal MACE risk were identified, and a parsimonious model efficiently encapsulated them. These findings may aid in assessing care processes to further improve care post-PCI outcomes. Full article

(This article belongs to the Special Issue Acute Coronary Syndrome (ACS): Guidelines and Evolving Concepts in the Diagnosis, Treatment and Management)

► Show Figures

Graphical abstract

12 pages, 1577 KiB

Open AccessArticle

The Impact of Emergency Department Arrival Time on Door-to-Balloon Time in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention

by Yu-Ting Hsiao, Jui-Fu Hung, Shi-Quan Zhang, Ya-Ni Yeh and Ming-Jen Tsai

J. Clin. Med. 2023, 12(6), 2392; https://doi.org/10.3390/jcm12062392 - 20 Mar 2023

Cited by 2 | Viewed by 3998

Abstract

Door-to-balloon (DTB) time significantly affects the prognosis of patients with ST-segment elevation myocardial infarction (STEMI). The effects of temporal differences in emergency department (ED) arrival time on DTB time and on different segments of DTB time remain inconclusive. Therefore, we performed a retrospective study in a tertiary hospital between January 2013 and December 2021 and investigated the relationship between a patient’s arrival time and both their DTB time and different segments of their DTB time. Of 732 STEMI patients, 327 arrived during the daytime (08:01–16:00), 268 during the evening (16:01–24:00), and 137 at night (00:01–08:00). Significantly higher odds of delay in DTB time were observed during the nighttime (adjusted odds ratio (aOR): 2.87; 95% confidence interval (CI): 1.50–5.51, p = 0.002) than during the daytime. This delay was mainly attributed to a delay in cardiac catheterization laboratory (cath lab) activation-to-arrival time (aOR: 6.25; 95% CI: 3.75–10.40, p < 0.001), particularly during the 00:00–04:00 time range. Age, sex, triage level, and whether patients arrived during the COVID-19 pandemic also had independent effects on different segments of DTB time. Further studies are required to investigate the root causes of delay in DTB time and to develop specific strategies for improvement. Full article

(This article belongs to the Special Issue Acute Coronary Syndrome (ACS): Guidelines and Evolving Concepts in the Diagnosis, Treatment and Management)

► Show Figures

Figure 1

14 pages, 1851 KiB

Open AccessArticle

GP IIb/IIIa Receptor Inhibitors in Mechanically Ventilated Patients with Cardiogenic Shock due to Myocardial Infarction in the Era of Potent P2Y12 Receptor Antagonists

by Vojko Kanic, Gregor Kompara and David Suran

J. Clin. Med. 2022, 11(24), 7426; https://doi.org/10.3390/jcm11247426 - 14 Dec 2022

Cited by 3 | Viewed by 1364

Abstract

Objective: To investigate the association between GP IIb/IIIa receptor inhibitors (GPI) and mortality and bleeding in patients with cardiogenic shock (CS) due to myocardial infarction (MI) who were mechanically ventilated on admission. Methods: We retrospectively divided 153 patients into two groups (with or without GPI). Thirty-day and one-year all-cause mortality and bleeding were studied. Results: The observed 30-day and one-year all-cause mortality were similar in both groups [54 (69.2%) with GPI vs. 62 (82.7%) without GPI; p = 0.06, and 60 (76.9%) with GPI vs. 64 (85.3%) without GPI; p = 0.22, respectively]. Patients with GPI suffered fewer unsuccessful PCI (TIMI 0/1 was 10% in the GPI group vs. 57% in the group without GPI), experienced more improvements in TIMI ≥ 1 flow [68 (87.2%) in the GPI group vs. 38 (50.7%) without GPI; p < 0.0001], and they achieved better cerebral performance category (CPC) scores (1.61 ± 0.99 with GPI vs. 2.76 ± 1.64 without GPI; p = 0.005). The bleeding rate was similar in patients with and without GPI [33 (42.3%) vs. 31 (41.3%): p = 1.00], in patients with P2Y12 receptor antagonists (P2Y12) [18 (46.1%) with GPI vs. 21 (46.7%) without GPI; p = 1.00], and in patients with potent P2Y12 [8 (30.8%) with GPI vs. 9 (37.5%) without GPI; p = 0.77]. Conclusions: Due to the study design (limited sample size, retrospective inclusion with high risk of selection bias), our analysis does not allow us to draw conclusions about the effectiveness of GPI in this context. Despite all these limitations, GPI were associated with improved TIMI flow after PCI in our multivariable model without increasing bleeding rates. In addition, better CPC scores were observed, but no association between GPI and outcome was found. Our analysis suggests that selective use of GPI may be beneficial in mechanically ventilated patients with MI in CS without additional bleeding risk, even in the era of potent P2Y12. Full article

(This article belongs to the Special Issue Acute Coronary Syndrome (ACS): Guidelines and Evolving Concepts in the Diagnosis, Treatment and Management)

► Show Figures

Figure 1

16 pages, 2004 KiB

Open AccessArticle

Incidence, Predictive Factors and Long-Term Clinical Impact of Left Ventricular Remodeling According to the Completeness of Revascularization in Patients with ST-Elevation Myocardial Infarction and Multivessel Disease

by Min Chul Kim, Yongwhan Lim, Youngkeun Ahn, Joon Ho Ahn, Seung Hun Lee, Dae Young Hyun, Kyung Hoon Cho, Doo Sun Sim, Young Joon Hong, Ju Han Kim and Myung Ho Jeong

J. Clin. Med. 2022, 11(21), 6252; https://doi.org/10.3390/jcm11216252 - 23 Oct 2022

Cited by 1 | Viewed by 1748

Abstract

In this study, we identified several factors related to left ventricular remodeling (LVR) and examined the impact of LVR on the prognosis of patients with ST-elevated myocardial infarction and multivessel disease treated with complete (CR) or incomplete (IR) revascularization. LVR was defined as an LV end-diastolic diameter >55 mm. A total of 262 patients without LVR at presentation were followed up with echocardiography between 1 month and 1 year. The primary outcome was a composite of all-cause death (AD), MI, and heart failure (HF), referred to as a major adverse cardiovascular endpoint (MACE). Then, each variable was analyzed as a secondary outcome. Follow-up echocardiography identified 26 patients (9.9%) with LVR. LVR was associated with an initial LV ejection fraction <50%, Killip 3 disease at presentation, and a peak troponin I level >70 mg/dL. Survival analysis showed an association between LVR and adverse outcomes only in the IR group, in which the adjusted hazard ratio (HR) was increased for the MACE (HR = 3.22, 95% confidence interval (CI) = 1.19–8.71, p = 0.002) and HF (HR = 21.37, 95% CI = 4.47–102.09, p< 0.001), but not for the CR group. In STEMI with MVD, LVR within the first year after percutaneous coronary intervention was associated with worse outcomes in the IR but not the CR group. Full article

(This article belongs to the Special Issue Acute Coronary Syndrome (ACS): Guidelines and Evolving Concepts in the Diagnosis, Treatment and Management)

► Show Figures

Figure 1

Review

Jump to: Editorial, Research

16 pages, 697 KiB

Open AccessReview

The Evolving Field of Acute Coronary Syndrome Management: A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome

by Roberto Licordari, Francesco Costa, Victoria Garcia-Ruiz, Mamas A. Mamas, Guillaume Marquis-Gravel, Jose M. de la Torre Hernandez, Juan Jose Gomez Doblas, Manuel Jimenez-Navarro, Jorge Rodriguez-Capitan, Cristobal Urbano-Carrillo, Luis Ortega-Paz, Raffaele Piccolo, Antonio Giovanni Versace, Gianluca Di Bella, Giuseppe Andò, Dominick J. Angiolillo, Marco Valgimigli and Antonio Micari

J. Clin. Med. 2024, 13(7), 1885; https://doi.org/10.3390/jcm13071885 - 25 Mar 2024

Cited by 2 | Viewed by 3901

Abstract

Acute coronary syndromes (ACS), encompassing conditions like ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndromes (NSTE-ACS), represent a significant challenge in cardiovascular care due to their complex pathophysiology and substantial impact on morbidity and mortality. The 2023 European Society of Cardiology (ESC) guidelines for ACS management introduce several updates in key areas such as invasive treatment timing in NSTE-ACS, pre-treatment strategies, approaches to multivessel disease, and the use of imaging modalities including computed tomography (CT) coronary angiography, magnetic resonance imaging (MRI), and intracoronary imaging techniques, such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS). They also address a modulation of antiplatelet therapy, taking into consideration different patient risk profiles, and introduce new recommendations for low-dose colchicine. These guidelines provide important evidence-based updates in practice, reflecting an evolution in the understanding and management of ACS, yet some potentially missed opportunities for more personalized care and technology adoption are discussed. Full article

(This article belongs to the Special Issue Acute Coronary Syndrome (ACS): Guidelines and Evolving Concepts in the Diagnosis, Treatment and Management)

► Show Figures

Journal Menu

Journal Browser

Acute Coronary Syndrome (ACS): Guidelines and Evolving Concepts in the Diagnosis, Treatment and Management

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (6 papers)

Editorial

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI